Skip to content

Effect of fish oil supplement on chronic atrial fibrillation

Assessment of serum levels of adiponectin and asymmetric dimethylarginine in patients with persistent and permanent atrial fibrillation following supplementation with fish oil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2012110411362N1
Enrollment
80
Registered
2012-12-03
Start date
2012-04-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation. Atrial fibrillation and flutter

Interventions

Intervention 1: intervention group: fish oil supplement, 2000mg for 8 weeks after a meal. Intervention 2: control group: olive oil placebo, 2000mg for 8 weeks after a meal.
Prevention
Placebo
intervention group: fish oil supplement, 2000mg for 8 weeks after a meal
control group: olive oil placebo, 2000mg for 8 weeks after a meal

Sponsors

School of Public Health, Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 81 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: postmenopausal women; men; above 50 years old; BMI higher than 25 kg/m2; patients without hyperthyroidism; patients without heart valve disorders; patients did not underwent coronary artery bypass surgery in the last three months; patients without heart failure of class IV; patients without history of alcohol abuse; not started taking in fish oil supplement within the three months before intervention; patients without allergy to fish oil Exclusion criteria: patients who stops taking supplement or placebo; patients who lose interest in participating in the study; patient who undergo coronary bypass

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Adiponectin. Timepoint: before intervention and 8 weeks after intervention. Method of measurement: µg/ml, elisa kit.;Asymmetric dimethylarginine (ADMA). Timepoint: before intervention and 8 weeks after intervention. Method of measurement: mol/Lµ, elisa kit.

Secondary

MeasureTime frame
HDL. Timepoint: before intervention and 8 weeks after intervention. Method of measurement: mg/dl, enzymatic.;LDL. Timepoint: before intervention and 8 weeks after intervention. Method of measurement: mg/dl, enzymatic.;Total cholesterol. Timepoint: before intervention and 8 weeks after intervention. Method of measurement: mg/dl, enzymatic.;VLDL. Timepoint: before intervention and 8 weeks after intervention. Method of measurement: mg/dl, Friedewald-Formel.;Triglyceride. Timepoint: before intervention and 8 weeks after intervention. Method of measurement: mg/dl, enzymatic.;Fasting blood sugar. Timepoint: before intervention and 8 weeks after intervention. Method of measurement: mg/dl, enzymatic.;Weight. Timepoint: before ivtervention and 8 weeks afte rintervention. Method of measurement: Seca scale, kg.;Bady mass index (BMI. Timepoint: before ivtervention and 8 weeks afte rintervention. Method of measurement: calculation, kg/cm2.;Waist circumference. Timepoint: waist Circumference. Method of measurement: meter tape, cm.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElnaz Khorrami

Department of Nutrition and Biochemistry

el-khorami@razi.tums.ac.ir+98 21 8895 1395

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026